Trade Summary

1 week ago, Chang David D, serving as Pres, CEO at Allogene Therapeutics, Inc. (ALLO), sold 47,763 shares at $2.47 per share, for a total transaction value of $117,975.00. Following this transaction, Chang David D now holds 8,063,795 shares of ALLO.

This sale represents a 1.00% decrease in Chang David D's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 18, 2026, 2 days after the trade was made.

Allogene Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.